Abstract
A drug-free interval is often recommended when switching monoamine oxidase inhibitors, although the evidence firmly supporting this caution has been minimal. A case is reported where an abrupt change in monoamine oxidase inhibitor was followed by the death of a patient.
Get full access to this article
View all access options for this article.
References
1.
Baldessarini
RJ
. Drugs and the treatment of psychiatric disorders . In:
Gilman
AG
Goodman
LS
Gilman
A
, eds. Goodman and Gilman's the pharmacological basis of therapeutics . 7th ed . New York : Macmillan , 1985 : 387 –445 .
2.
Sheehan
DV
Claycomb
JB
. The use of MAO inhibitors in clinical practice . In:
Manschreck
T
, ed. Psychiatric medicine update . New York : Elsevier , 1984 : 143 –62 .
3.
Reynolds
JEF
, ed. Martindale: the extra pharmacopoeia . London : Pharmaceutical Press , 1982 : 129 .
4.
Nardil
Parnate
. Physicians' desk reference . Oradell, NJ : Medical Economics Company , 1986 : 1368 –9 , 1719 –21 .
5.
True
BL
Alexander
B
Carter
B
. Switching monoamine oxidase inhibitors . Drug Intell Clin Pharm
1985 ; 19 : 825 –7 .
6.
Gelenberg
AJ
. Switching MAOI . Biol Ther Psychiatr
1984 ; 7 : 36 .
7.
Burke
RE
Fahn
S
Mayeux
R
Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntingdon disease . Neurology
1981 ; 31 : 1022 –6 .
8.
Gibbs
WRG
Griffith
DNW
. Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome . Postgrad Med J
1986 ; 62 : 59 –60 .
9.
Friedman
JH
Feinberg
SS
Feldman
RG
. A neuroleptic malignant syndrome-like syndrome due to levodopa therapy withdrawal . JAMA
1985 ; 254 : 2792 –5 .
10.
Grant
R
. Neuroleptic malignant syndrome (letter) . Br Med J
1984 ; 288 : 1690 .
11.
Reddi
K
. Neuroleptic malignant syndrome (letter) . Br Med J
1984 ; 288 : 1690 .
12.
Itoh
H
Ohusuka
N
Ogita
K
. Neuroleptic malignant syndrome: its present status in Japan and clinical problems . Folia Psychiatr Neurol Jpn
1977 ; 31 : 565 –76 .